Chuvashia Inappropriate Prescribing Study

This is a cross-sectional study based on an outpatient registry. All medical therapy will be registered in order to assess inappropriate prescribing's, in accordance with the criteria PROMPT and BEERS, also in accordance with the officially approved instructions for the use of this medicinal product.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Multimorbidity, Cardiovascular Diseases Amino Acid Metabolism, Inborn Errors Brain Diseases Brain Diseases, Metabolic Brain Diseases, Metabolic, Inborn Cardiovascular Diseases Central Nervous System Diseases Congenital, Hereditary, and Neonatal Diseases and Abnormalities Genetic Diseases, Inborn Genetic Diseases, X-Linked Metabolic Diseases Metabolism, Inborn Errors Nervous System Diseases Nutritional and Metabolic Diseases Ornithine Carbamoyltransferase Deficiency Disease Urea Cycle Disorders, Inborn

Age range

50 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Respublikanski Kardiologicheski Dispanser Minzdrava Chuvashii

Cheboksary, Russia

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age > 50 years old, multimorbidity, signed Patients' Informed Consent

Exclusion criteria

Age < 50 years, presence of mental illnesses, oncological diseases detected less than 5 years ago, acute cardiovascular pathology within 6 months prior to inclusion.

Treatment and study plan

Primary outcomes

frequency of inappropriate drug prescriptions

Time frame: Assessed at baseline

Рrescribing medications in an inadequate dose, with the wrong frequency, and the wrong duration of treatment, failure to prescribe a potentially effective drug in the presence of clinical indications, self-medication was considered irrational treatment and was assessed as the end point.

It also includes prescribing medications that are likely to have a negative effect on the course of concomitant pathology, as well as drug interactions, in accordance with the criteria PROMPT and BEERS.

Sponsors and collaborators

Lead sponsor

National Medical Research Center for Therapy and Preventive Medicine

Other Gov

Collaborators

BU "Respublikanski Kardiologicheski Dispanser" Minzdrava Chuvashii, Cheboksary

Registry information

Acronym: CHIP

Important dates

Study start: 2023
Primary completion: 2024
Study completion: 2024
First posted: Feb 25, 2025
Registry last updated: Jun 10, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed